PKN3 and neoplasm: As protein kinase N3 has previous been identified as a downstream effector of the PI3K signaling pathway, reduction of protein kinase N3 expression with Atu027 resulted in changes in tumor lymphatic vasculature, suggesting an anti-lymph angiogenesis therapeutic strategy for pancreatic cancer [115].